Today's News |
Arbutus Biopharma Moves Head Office to USA and Closes BC Location
Thursday, October 17, 2019
Burnaby, BC, October 17, 2019--(T-Net)--A representative of Arbutus Biopharma reported to T-Net that the company has moved its head office to the USA, and is no longer operating their previous BC location.
The company representative did not report when the move took place.
About Arbutus Biopharma
Arbutus Biopharma Corporation (NASDAQ: ABUS) is a publicly-traded biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV).
We are developing a portfolio of drug candidates with complementary mechanisms of action that we believe will result in our first novel combination regimen that will transform the HBV treatment landscape and cure hepatitis B virus disease.
Other Recent Company News |
|||||||||||||||||||
|